MELISA and Lymphocyte Blood Tests for Dental Materials: What Results Can and Cannot Show

Direct answer

MELISA is a laboratory variation of the lymphocyte transformation test. It can show in-vitro lymphocyte reactivity under the laboratory's conditions, but it does not prove that the same response is causing a patient's oral or systemic symptoms. Preanalytic variation, material preparation, limited standardization, and uncertain predictive value restrict routine use.

Key takeaways

MELISA is an in-vitro immune assay, not a direct measurement of what is happening around the implant.
An abnormal result may indicate laboratory reactivity without demonstrating clinical disease or causation.
A normal result does not exclude particle-driven innate inflammation, infection, mechanical problems, or another material reaction.
Results are sensitive to blood handling, medications, antigen concentration, controls, and laboratory-specific cutoffs.
Testing should be ordered only when the question is specific and the result could meaningfully alter management.

Evidence and decision snapshot

Evidence and decision snapshot for MELISA and Other Blood Tests for Dental Materials
Question	Established role	Possible value	Important limitation
What is measured	Lymphocyte proliferation or activation after exposure to a laboratory-prepared material.	Can identify an immune signal worth correlating clinically.	Does not reproduce bone, saliva, plaque, corrosion, or device mechanics.
Positive result	Above the laboratory threshold relative to controls.	May support further specialist evaluation.	Does not prove the implant is the source or that removal will help.
Negative result	No measured response under the assay conditions.	May reduce suspicion of the tested adaptive response.	Does not exclude other immune pathways or an untested component.
Best role	Adjunct in selected unresolved cases.	Adds one data point to a multidisciplinary assessment.	Not a population screening or device-selection guarantee.

How lymphocyte transformation testing works

Blood is collected and peripheral blood mononuclear cells are isolated. The cells are cultured with a test substance and compared with negative and positive controls. Proliferation or activation is converted to a stimulation index or another laboratory value. MELISA adds proprietary processing and microscopic evaluation to the general LTT concept.

The appealing idea is personalized evidence: expose the patient's cells to a material before or after implantation. The limitation is that the test system simplifies a complex exposure. The chemical species presented to cells, its concentration, particle size, protein binding, and solubility may differ substantially from what occurs at an implant.

Why preanalytic conditions matter

Living-cell assays are sensitive to transport temperature, time from collection to processing, sample volume, infection, immune-suppressing medication, corticosteroids, recent vaccination, and cell viability. Laboratories may have different acceptance criteria and control ranges. A delayed or stressed sample can produce an uninterpretable or misleading result.

The tested metal preparation matters equally. Elemental titanium, titanium dioxide particles, corrosion products, soluble salts, and alloying elements do not produce identical exposures. Without a standardized clinically relevant antigen, an assay may answer a different question from the one the patient is asking.

What a positive result means

A positive result means the cultured cells responded above the laboratory's chosen threshold. It may indicate prior sensitization, nonspecific activation, cross-reactivity, an assay artifact, or a clinically relevant response. The result does not establish where exposure occurred or whether the implant is responsible for current symptoms.

Clinical relevance becomes stronger when the tested material is documented in the device, the symptoms began after exposure, the pattern is biologically plausible, common causes have been excluded, and independent findings support the same mechanism. Even then, causation may remain uncertain.

What a negative result means

A negative result means no qualifying lymphocyte response was detected under those assay conditions. It does not exclude innate macrophage activation by particles, local tissue toxicity, infection, galvanic corrosion, mechanical wear, or allergy to a material that was not tested. It also does not guarantee that future implantation will be symptom-free.

This limitation is particularly important because the German guideline conceptualizes many suspected titanium intolerance reactions as local innate inflammatory responses rather than classic adaptive allergy. A lymphocyte test may therefore be biologically mismatched to the proposed process.

Testing panels can create incidental findings

Broad panels often test many metals or dental chemicals. The more substances tested, the greater the chance of finding at least one abnormal value that is unrelated to the patient's device or symptoms. Incidental positivity can lead to restrictive material lists, anxiety, and removal of restorations that were not causing disease.

A better approach begins with an inventory of actual exposures. The implant identification record, abutment alloy, fixation screw, restorative framework, crown, cement, provisional resin, endodontic materials, and adjacent restorations should guide the panel.

A decision-focused use of laboratory testing

Before ordering the test, write the clinical question: for example, whether a documented cobalt-containing suprastructure may be contributing to a localized contact reaction. Decide what result would change treatment and what would not. Arrange specialist interpretation rather than allowing a laboratory report to become the diagnosis.

For pre-implant planning, material preference and a history of severe documented metal contact allergy may justify choosing a suitable ceramic system without relying on an unvalidated blood compatibility screen. Device selection still requires evidence for the exact ceramic implant and its components.

Frequently asked questions

Is MELISA the same as a standard blood allergy test?

No. It is a cellular laboratory assay and is not equivalent to validated IgE testing for immediate allergies.

Can MELISA predict whether a ceramic implant will work?

No. It cannot predict osseointegration, fracture, infection, positioning, or restoration success.

Can medications affect the result?

Yes. Immune-modifying drugs, corticosteroids, illness, and sample-handling factors may influence cell response.

Should I remove an implant because one metal is positive?

Not without confirming that the material is present, clinically relevant, and more likely than alternative explanations.

What is the best use of the test?

A narrowly defined adjunctive question interpreted within a multidisciplinary clinical evaluation.

Questions to discuss with your implant and medical team

What exact clinical question is this test intended to answer?
Which actual device materials will be tested?
How quickly must the sample reach the laboratory?
How are borderline and positive values validated and reproduced?
What treatment decision would change because of the result?

What this means for patients

MELISA and related blood assays measure a laboratory immune response, not implant compatibility as a whole. Their best role is limited and adjunctive. Results should never be used alone to diagnose systemic toxicity or mandate implant removal.